|
Name |
Rhizovarin D
|
Molecular Formula | C38H51NO5 | |
IUPAC Name* |
(1S,2R,5R,7R,8R,11R,14S)-8,11-dihydroxy-18-[(1S,2S,4S)-2-(2-hydroxypropan-2-yl)-4-prop-1-en-2-ylcyclobutyl]-1,2-dimethyl-7-prop-1-en-2-yl-23-azapentacyclo[12.10.0.02,11.05,10.017,22]tetracosa-9,17,19,21-tetraene-16,24-dione
|
|
SMILES |
CC(=C)[C@H]1C[C@H]2CC[C@@]3([C@@]4([C@@H](CC[C@]3(C2=C[C@H]1O)O)CC(=O)C5=C(C=CC=C5NC4=O)[C@H]6[C@H](C[C@@H]6C(C)(C)O)C(=C)C)C)C
|
|
InChI |
InChI=1S/C38H51NO5/c1-20(2)25-16-22-12-14-36(7)37(8)23(13-15-38(36,44)27(22)19-30(25)40)17-31(41)33-24(10-9-11-29(33)39-34(37)42)32-26(21(3)4)18-28(32)35(5,6)43/h9-11,19,22-23,25-26,28,30,32,40,43-44H,1,3,12-18H2,2,4-8H3,(H,39,42)/t22-,23+,25-,26-,28+,30-,32+,36-,37-,38-/m1/s1
|
|
InChIKey |
AFDVDYAFHXSLEK-OPQRZYFNSA-N
|
|
Synonyms |
Rhizovarin D
|
|
CAS | NA | |
PubChem CID | 139589621 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 601.8 | ALogp: | 5.1 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 107.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 44 | QED Weighted: | 0.289 |
Caco-2 Permeability: | -4.802 | MDCK Permeability: | 0.00001370 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.857 |
Human Intestinal Absorption (HIA): | 0.343 | 20% Bioavailability (F20%): | 0.933 |
30% Bioavailability (F30%): | 0.049 |
Blood-Brain-Barrier Penetration (BBB): | 0.337 | Plasma Protein Binding (PPB): | 86.93% |
Volume Distribution (VD): | 1.806 | Fu: | 5.37% |
CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.729 |
CYP2C19-inhibitor: | 0.219 | CYP2C19-substrate: | 0.792 |
CYP2C9-inhibitor: | 0.553 | CYP2C9-substrate: | 0.063 |
CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.092 |
CYP3A4-inhibitor: | 0.946 | CYP3A4-substrate: | 0.892 |
Clearance (CL): | 8.612 | Half-life (T1/2): | 0.01 |
hERG Blockers: | 0.711 | Human Hepatotoxicity (H-HT): | 0.528 |
Drug-inuced Liver Injury (DILI): | 0.423 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.941 | Maximum Recommended Daily Dose: | 0.948 |
Skin Sensitization: | 0.078 | Carcinogencity: | 0.865 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.945 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003330 | 0.478 | D02IQY | 0.259 | ||||
ENC003329 | 0.472 | D0I2SD | 0.238 | ||||
ENC003833 | 0.397 | D06AEO | 0.234 | ||||
ENC000836 | 0.377 | D0W2EK | 0.231 | ||||
ENC001492 | 0.367 | D0V4WD | 0.231 | ||||
ENC001486 | 0.356 | D04SFH | 0.230 | ||||
ENC005406 | 0.355 | D04GJN | 0.230 | ||||
ENC002746 | 0.351 | D0F7NQ | 0.227 | ||||
ENC003834 | 0.348 | D0Q6NZ | 0.225 | ||||
ENC003660 | 0.338 | D0X7XG | 0.225 |